ESG Landscape in the Biopharma Industry
ESG Landscape in the Biopharma Industry
Understand the ESG risks and impact with our comprehensive Biopharma Report
How much do you really know about biopharma? We've evaluated the financial impact of ESG risks on biotechnology, drug manufacturers, and pharmaceutical firms, focusing on pricing cuts and litigation expenses. These firms provide essential, life-dependent products, making failures potentially life-threatening and financially severe for consumers. Vulnerable groups like children and seniors are disproportionately affected by adverse outcomes, leading to higher scrutiny and litigation risk, especially in litigious countries like the U.S.
Our top-tier data from Sustainalytics estimates top biopharmaceutical firms generally have low or medium ESG risk ratings; GSK, Novartis, and Regeneron holding the lowest rating and AbbVie with one of the highest risk ratings. Our analysts the average cumulative probability-weighted materiality of ESG risks across firms at 10.8%. Bayer faces the highest ESG risk due to drug pricing and litigation risks, particularly from Roundup herbicide litigation, while Vertex and BioMarin have limited ESG risk as their drugs target life-threatening rare diseases and have minimal Medicare exposure.
From sustainability initiatives to ethical considerations and corporate governance, our report equips you with the knowledge to make informed decisions in the evolving ESG landscape of biopharma. Read about it all now.
What's Inside:
What's Inside:
- A detailed analysis of critical ESG risks for biopharma companies, including product governance, access to essential services, and business ethics.
- An examination of the U.S. market's influence on global drug sales, and the impact of drug pricing across various regions.
- Our exclusive capsule system for identifying biopharma companies facing pricing risks, coupled with our unique moat ratings for these firms.